Filing Details

Accession Number:
0000899243-20-028430
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-10-15 20:24:39
Reporting Period:
2020-10-13
Accepted Time:
2020-10-15 20:24:39
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1701108 Spero Therapeutics Inc. SPRO Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1720974 Ankit Mahadevia C/O Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14Th Floor
Cambridge MA 02139
Ceo And President Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-10-13 14,367 $5.90 80,184 No 4 M Direct
Common Stock Disposition 2020-10-13 14,367 $14.28 65,817 No 4 S Direct
Common Stock Acquisiton 2020-10-14 105 $5.90 65,922 No 4 M Direct
Common Stock Disposition 2020-10-14 105 $14.25 65,817 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-10-13 14,367 $0.00 14,367 $5.90
Common Stock Stock Option (Right to Buy) Disposition 2020-10-14 105 $0.00 105 $5.90
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
504,441 2027-07-05 No 4 M Direct
504,336 2027-07-05 No 4 M Direct
Footnotes
  1. All transactions reported on this Form 4 were made pursuant to a previously adopted Rule 10b5-1 trading plan. Specifically, the transactions reported herein relate to option exercises and related sales (totaling 14,472 shares).
  2. Amount includes shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.
  3. The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.25 to $14.52 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  4. All of the option exercises reported herein were made with respect to options granted pursuant to the Company's 2017 Equity Incentive Plan on July 6, 2017 with vesting schedules generally consisting of 25% cliff vesting on specified dates and with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.